Sequenta Readies ClonoSight for 2013 Launch with CLIA Certification and Clinical Validation Studies | GenomeWeb

With CLIA certification and several validation studies under its belt, Sequenta is gearing up for the 2013 launch of its sequencing-based test to detect minimal residual disease in cancer patients.

The company plans to launch its test, which it has named ClonoSight, as a service from its CLIA-certified laboratory in South San Francisco. It will initially focus on patients with acute lymphocytic leukemia, mantle cell leukemia, and chronic lymphocytic leukemia, but plans to expand to all blood cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.